

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 26, 2011

---

**Protalix BioTherapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

Florida  
(State or other jurisdiction  
of incorporation)

001-33357  
(Commission File Number)

65-0643773  
(IRS Employer  
Identification No.)

2 Snunit Street  
Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices)

20100  
(Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Item 7.01. Regulation FD Disclosure

On October 26, 2011, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that senior management will present at four upcoming conferences:

### Ernst & Young Journey 2011 Conference

Wednesday, November 2, 2011 at 2:45 PM IDT

Topic: The Pfizer-Protalix Gaucher Collaboration – The Partners’ Point of View

Dr. David Aviezer, President & CEO

Hilton Hotel, Tel-Aviv, Israel

### PDA-Parenteral Drug Association / FDA-Food and Drug Administration:

#### Adventitious Agents and Novel Cell Substrates Conference

Thursday, November 3, 2011 at 1:15-3:15 PM ET

Topic: Potential Safety and Quality Issues Related to Plants and Plant-Based Products

Dr. Yoseph Shaaltiel, Executive Vice President, R&D

Hilton Washington DC / Rockville Hotel & Executive Meeting Center, Rockville, MD, USA

### Lazard Capital Markets 8th Annual Healthcare Conference

Wednesday, November 16, 2011 at 1:30 PM ET

Topic: Corporate Presentation

Mr. Yossi Maimon, CFO

Pierre Hotel, New York, NY, USA

*A webcast of this presentation will be available at [www.protalix.com](http://www.protalix.com) on the event calendar page. A replay will be archived and available after the conference for 30 days.*

### World Orphan Drug Congress

Thursday, December 1, 2011 at 10:10 AM CEST

Topic: Regulatory Expectations and Clinical Strategy for Treating Fabry Disease

Dr. David Aviezer, President & CEO

Crowne Plaza Hotel, Geneva, Switzerland

A copy of the press release is furnished as Exhibit 99.1.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

## Item 9.01. Financial Statements and Exhibits

### (d) Exhibits

99.1 Press release dated October 26, 2011

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **PROTALIX BIOTHERAPEUTICS, INC.**

Date: October 26, 2011

By: /s/ Yossi Maimon  
Name: Yossi Maimon  
Title: Chief Financial Officer

## Protalix BioTherapeutics to Present at Four Upcoming Conferences

CARMIEL, Israel, October 26, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that senior management will present at four upcoming conferences:

### Ernst & Young Journey 2011 Conference

Wednesday, November 2, 2011 at 2:45 PM IDT

Topic: The Pfizer-Protalix Gaucher Collaboration – The Partners' Point of View

Dr. David Aviezer, President & CEO

Hilton Hotel, Tel-Aviv, Israel

### PDA-Parenteral Drug Association / FDA-Food and Drug Administration:

#### Adventitious Agents and Novel Cell Substrates Conference

Thursday, November 3, 2011 at 1:15-3:15 PM ET

Topic: Potential Safety and Quality Issues Related to Plants and Plant-Based Products

Dr. Yoseph Shaaltiel, Executive Vice President, R&D

Hilton Washington DC / Rockville Hotel & Executive Meeting Center, Rockville, MD, USA

### Lazard Capital Markets 8th Annual Healthcare Conference

Wednesday, November 16, 2011 at 1:30 PM ET

Topic: Corporate Presentation

Mr. Yossi Maimon, CFO

Pierre Hotel, New York, NY, USA

*A webcast of this presentation will be available at [www.protalix.com](http://www.protalix.com) on the event calendar page. A replay will be archived and available after the conference for 30 days.*

### World Orphan Drug Congress

Thursday, December 1, 2011 at 10:10 AM CEST

Topic: Regulatory Expectations and Clinical Strategy for Treating Fabry Disease

Dr. David Aviezer, President & CEO

Crowne Plaza Hotel, Geneva, Switzerland

## About Protalix

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx™. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner in an environment free of mammalian components and viruses. Protalix's lead compound, taliglucerase alfa, an enzyme replacement therapy for the treatment of Gaucher disease, completed Phase III development. To date, marketing applications have been submitted for taliglucerase alfa in the United States, the European Union, Brazil, Israel and Australia. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel™) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others. Protalix's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 1, 2012.

## **Forward Looking Statements**

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms “anticipate,” “believe,” “estimate,” “expect” and “intend” and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. The statements in this release are valid only as of the date hereof and we disclaim any obligation to update this information.

---

## **Investor Contact**

Marcy Nanus  
The Trout Group, LLC  
646-378-2927  
mnanus@troutgroup.com

## **Media Contact**

Jennifer Conrad or Douglas MacDougall  
MacDougall Biomedical Communications  
781-235-3060  
jconrad@macbiocom.com